Iovance Biotherapeutics, Inc. - Common Stock (IOVA)

Gross margin hit a record as AMTAGVI demand pushed revenue higher.

Iovance Biotherapeutics (NASDAQ:IOVA) reported record third-quarter revenue of approximately $122 million, up 80% from a year earlier, as sales of its melanoma treatment AMTAGVI surpassed $100 million in a quarter for the first time. The company reaffirmed its 2026 revenue guidance of $410 million

These biotechs’ valuations are through the roof.

Iovance Biotherapeutics (NASDAQ:IOVA) reported updated data from its registrational IOV-LUN-202 trial of lifileucel in previously treated, non-squamous metastatic non-small cell lung cancer, outlining plans for a supplemental Biologics License Application submission in 2027 and a new biomarker-enric

An influential investment bank resumed its coverage of the company.

Iovance Biotherapeutics (NASDAQ:IOVA) said it is expanding its tumor-infiltrating lymphocyte, or TIL, therapy platform across multiple solid-tumor indications after reporting a record second quarter marked by nearly $100 million in revenue and a 56% margin. Speaking at the H.C. Wainwright 28th Annu

Record Amtagvi revenue and gross margins signal strong commercial momentum in cell therapy.

The healthcare stock is now up more than 130% this year.

Iovance Biotherapeutics (NASDAQ:IOVA) reported record second-quarter revenue and gross margin, driven by demand for its Amtagvi tumor-infiltrating lymphocyte, or TIL, therapy, as the company expanded its treatment-center network and advanced clinical programs in lung cancer, sarcoma and gynecologic

Iovance Biotherapeutics Inc (NASDAQ:IOVA) shares are surging Thursday after the cancer therapy company shattered second-quarter expectations on both the top and bottom lines. Here's what you should know.

The biotech is clearly innovative, but sometimes that's not enough.

Heartflow scales AI diagnostics while Iovance drives personalized cancer therapies, each faces unique financial and operational risks in 2026.

Weigh the financial strength of a pharma leader against the rapid growth, and risks, of a biotech newcomer as both navigate industry headwinds.